EZH2 as a potential therapeutic target for gastrointestinal cancers
M Hashemi, N Nazdari, G Gholamiyan… - … -Research and Practice, 2023 - Elsevier
Gastrointestinal (GI) cancers continue to be a major cause of mortality and morbidity
globally. Understanding the molecular pathways associated with cancer progression and …
globally. Understanding the molecular pathways associated with cancer progression and …
[HTML][HTML] Construction of a circadian rhythm-relevant gene signature for hepatocellular carcinoma prognosis, immunotherapy and chemosensitivity prediction
Z Ye, Y Du, W Yu, Y Lin, L Zhang, X Chen - Heliyon, 2024 - cell.com
Aims This study explored the molecular and biologic mechanisms underlying the
association between circadian rhythm disorders (CRD) and increased risk for hepatocellular …
association between circadian rhythm disorders (CRD) and increased risk for hepatocellular …
[HTML][HTML] EZH2 抑制剂与膀胱癌GC 化疗药物联用增敏的作用研究
谢峻， 刘绍有， 施鸿金， 毛秋玉， 杨宏 - 昆明医科大学学报, 2023 - kyxuebao.kmmu.edu.cn
目的探究多梳蛋白zeste 基因増强子类同源物2 (histone methyltransferase enhancer of Zeke
2, EZH2) 抑制剂对膀胱癌治疗中吉西他滨联合顺铂(gemcitabine and cisplatin, GC) …
2, EZH2) 抑制剂对膀胱癌治疗中吉西他滨联合顺铂(gemcitabine and cisplatin, GC) …